What are the relative risks and benefits of progestin-only contraceptives? by Roederer, Mary W. & Blackwell, Jean
806 VOL 54, NO 9 / SEPTEMBER 2005  THE JOURNAL OF FAMILY PRACTICE
CLINICAL INQUIRIES
E V I D E N C E - B A S E D A N S W E R
What are the relative risks and benefits 
of progestin-only contraceptives?
■ Evidence summary
The risks and benefits associated with
progestin-only contraceptives are not 
completely studied for all routes of admin-
istration. There is insufficient evidence
regarding their risks to point to a definitive
harm with their administration (TABLE). 
The risk of pregnancy with progestin-
only contraceptives ranges from 0.0% to
13.2% based on the method that is 
selected.8 Evidence is lacking to support
use of progestin-only contraceptives for
premenstrual syndrome or dysfunctional
uterine bleeding.6,7
Little evidence describes the risks and 
benefits of progestin-only contraceptives 
therapy options. 
Risks
No good-quality evidence exists to determine the
risk of cancer associated with progestin-only 
contraceptives. Data are insufficient to discern 
their effect on milk quality and quantity during 
lactation, though no effect on infant growth or
weight was identified (strength of recommendation
[SOR]: A, based on systematic Cochrane review).1
No increase in blood pressure occurred with
oral progestin-only contraceptives or depot
medroxyprogesterone acetate (DMPA) (SOR: B,
cohort studies).2 A decrease in bone mineral 
density was associated with current use of DMPA
in studies lasting 2 years or less, yet the cessation
of use may attenuate the effect (SOR: B, mostly
case-control).3 Oral and injectable progestin-only
contraceptives demonstrated no significant
increase in venous thromboembolism, stroke,
acute myocardial infarction, or combined 
cardiovascular disease endpoint (SOR: B, 
case-control study).4 Termination rates for 
nonmenstrual effects with progesterone implants
were less than 3% (SOR: B, cohort studies).5
Benefits
Progestin-only contraceptives are an effective form
of birth control. For the treatment of premenstrual
syndrome or dysfunctional uterine bleeding, 
inadequate evidence exists to support using 
progestin-only options (SOR: A, RCTs).6,7
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C L I N I C A L C O M M E N T A R Y
Patient-centered, not evidence-based, reasons 
contribute to shifts in contraception patterns
Nonlactating women in my practice are choosing
progestin-only contraceptives less often than 
previously, when DMPA was my second-most-
common contraceptive prescription. Patient-
centered, not evidence-based, reasons contribute 
to this shift in prescribing patterns.
Many women who chose injectable 
progestin-only contraceptives because of difficulty
remembering to take oral contraceptives have
changed to patch-delivered or intravaginal 
estrogen-progestins due to concern over potential
weight gain and increased bone loss with 
progestin-only contraceptives. Intrauterine devices
have experienced a surge in popularity with the
addition of slow-release progesterone, and 
condoms remain popular because they reduce 
disease transmission. When women receive 
evidence-based risk/benefit contraceptive 
counseling, they then have the knowledge to
choose the contraceptive that best fits their lifestyle.
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Recommendations from others
The World Health Organization (WHO)
highlights the need to avoid progestin-only
contraceptives for women younger than 18
or older than 45 years, secondary to con-
cerns of decreased bone mass. Immediately
postpartum, women may initiate progestin-
only contraceptives if they are not breast-
feeding; if breastfeeding, women should
wait until at least 6 months postpartum. 
Hypertensive women should avoid
progestin-only contraceptives; women at
risk for hypertension—particularly DMPA
users—are encouraged to measure blood
pressure before and after use. The WHO
document points out the increased possibil-
ity for abnormal uterine bleeding with 
progestin-only contraceptives use.9
American College of Physician’s PIER:
Physicians’ Information and Education
Resource describes using progestin-only
contraceptives in hypercoagulable states
and severe hyperlipidemia and avoiding
use in osteoporosis, osteopenia, and chron-
ic glucocorticoid use due to a decrease in
bone mineral density.10
T A B L E
RISK TYPE EVIDENCE
VTE, stroke, acute MI, Oral injectable No significant association with increased incidence of VTE, 
or combined CVD endpoint4 stroke, acute MI, or the combined CVD endpoint
Increased blood pressure2 Oral DMPA No significant association with increased blood pressure 
for up to 2–3 years of use
Nonmenstrual adverse events5 Progesterone • Specific information for each adverse event unavailable
• Headache implants • Overall termination rate for nonmenstrual adverse events 
• Lower abdominal pain less than 3%
• Weight gain
• Acne
Effect on lactation1 All progestin-only • Insufficient evidence to establish an effect on milk quality 
contraceptives* or quantity
• No documented effect on infant growth or weight
Decreased BMD3 DMPA • Decreased bone mineral density within 1 standard 
deviation of mean 
• Duration of effect inconclusive as cessation of use 
may attenuate effect
• No information on risk of fracture
Pregnancy8 Oral, DMPA, Based on perfect use and typical use evaluations:
progesterone • Oral: 0.0% to 13.2%
implants • DMPA: 0.0% to 3.2%
• Implants: 0.0% to 2.3%
BENEFIT TYPE EVIDENCE
Treatment of PMS6 Suppositories, No evidence of improvement in PMS symptoms
pessaries, oral
Dysfunctional uterine Oral No evidence to support the use of progesterones or
bleeding with anovulation7 progestogens in dysfunctional uterine bleeding
*Only trials with oral dosages met criteria.
DMPA, depot medroxyprogesterone acetate; VTE, venous thromboembolism; MI, myocardial infarction; CVD, cardiovascular disease; 
PMS, premenstrual syndrome
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THE JOURNAL OF FAMILY PRACTICE uses 
a simplified rating system called the 
Strength of Recommendation Taxonomy
(SORT). More detailed information can 
be found in the February 2003 issue,
“Simplifying the language of patient care,”
pages 111–120.
Strength of Recommendation (SOR) ratings
are given for key recommendations for readers.
SORs should be based on the highest-quality 
evidence available.
A Recommendation based on consistent and 
good-quality patient–oriented evidence.
B Recommendation based on inconsistent or 
limited-quality patient-oriented evidence.
C Recommendation based on consensus, usual practice,
opinion, disease-oriented evidence, or case series for 
studies of diagnosis, treatment, prevention, or screening
Levels of evidence determine whether a study
measuring patient-oriented outcomes is of
good or limited quality, and whether the results
are consistent or inconsistent between studies.
STUDY QUALITY
1—Good-quality, patient-oriented evidence 
(eg, validated clinical decision rules, systematic reviews 
and meta-analyses of randomized controlled trials
[RCTs] with consistent results, high-quality RCTs, or
diagnostic cohort studies)
2—Lower-quality patient-oriented evidence 
(eg, unvalidated clinical decision rules, lower-quality 
clinical trials, retrospective cohort studies, case control
studies, case series)
3—Other evidence (eg, consensus guidelines, usual 
practice, opinion, case series for studies of diagnosis,
treatment, prevention, or screening)
Consistency across studies 
Consistent—Most studies found similar or at least 
coherent conclusions (coherence means that differences
are explainable); or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they support
the recommendation
Inconsistent—Considerable variation among study findings
and lack of coherence; or If high-quality and up-to-date 
systematic reviews or meta-analyses exist, they do not 
find consistent evidence in favor of the recommendation
Evidence-based medicine ratings
The American College of Obstetricians and
Gynecologists (ACOG) specifically endorses the pref-
erential use of progestin-only contraceptives by lactat-
ing women and women at an increased risk of venous
thromboembolism based on good evidence. For
women with systemic lupus erythematosus, ACOG
recommends use of progestin-only contraceptives over
combined oral contraceptive, based on fair evidence.
By consensus, ACOG recognizes benefits of DMPA
for women with sickle-cell disease and women with
coronary artery disease, congestive heart failure, or
cerebrovascular disease. In general, ACOG recom-
mends progestin-only contraceptives over combined
oral contraceptives for patients with the following
conditions: migraine headaches, cigarette smoker of
age greater than 35, history of venous thrombo-
embolism, coronary artery disease, congestive heart
failure, cerebrovascular disease, postpartum <2 weeks,
hypertension with vascular disease or age greater 
than 35, diabetes with vascular disease or age 
greater than 35, systemic lupus erythematosus with
vascular disease, nephritis, or antiphospholipid anti-
bodies, or hypertriglyceridemia.11
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